Advancing Global Health

Gilead recognizes that the development of innovative medicines for life-threatening diseases is only one aspect of improving public health. We also invest in programs that promote prevention, strengthen healthcare infrastructure, and provide education and financial support to the most vulnerable communities around the world.

By enabling access to medicines, challenging assumptions, fighting stigma and collaborating with partners worldwide, we work not simply to treat some of the world’s most challenging public health threats – but to eliminate them.

Expanding Treatment Access in Low- and Middle-Income Countries

Gilead is committed to meeting with public health officials, doctors and patients around the world to understand barriers and opportunities in HIV, viral hepatitis and visceral leishmaniasis (VL).

Expanding Treatment Access in Low- and Middle-Income Countries


Addressing HIV in Eastern Europe & Central Asia – RADIAN

RADIAN is our ground-breaking partnership with the Elton John AIDS Foundation to address new HIV transmissions and deaths from HIV-related illnesses in Eastern Europe & Central Asia. Through this program, we seek to improve the quality of prevention and care for people at risk of or living with HIV.

Keeping Girls and Young Women HIV-Free in Sub-Saharan Countries

Gilead partners with the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) to help reduce HIV in adolescent girls and young women in 10 sub-Saharan African countries.

Keeping Girls and Young Women HIV-Free in Sub-Saharan Countries

Helping Eliminate Chronic Hepatitis C Worldwide

The WHO has set the goal of eliminating viral hepatitis worldwide by 2030. Through awareness, screening and care, we’re helping governments, patients and payers in efforts to eliminate the chronic hepatitis C virus (HCV) and eradicate the disease.

Gilead and the WHO Tackle VL in Southeast Asia

Visceral leishmaniasis (VL) is a parasitic disease. An estimated 50,000 to 90,000 new cases occur worldwide each year, but it is estimated that only 25-45% of those cases are reported. VL is almost always fatal if untreated. We are collaborating with the World Health Organization (WHO) to provide our medicines free of charge to all patients diagnosed with the disease.

50,000-90,000 new cases occur each year, but only 25-45% are reported